According to an interim analysis of the TOPAZ-1 trial, the tumor area that was PD-L1-positive was smaller in the durvalumab arm than in the placebo arm (60.9% vs. 67.3%), indicating that the prolonged OS observed in the durvalumab arm among patients with BTC was independent of PD-L1 positivity in the tumor tissue. The gene discussed is CD274; the disease is neoplasm.